Screener
Lexicon Pharmaceuticals LXRX Business Segments — Loss from operations
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| General and administrative | 6,964 | 6,466 | 13,408 | 14,292 |
| Other segment expense (1) | 3,336 | 3,271 | 6,414 | 6,072 |
| Total operating expenses | 27,232 | 25,130 | 49,330 | 52,071 |
| (Loss) income from operations | (26,540) | 3,736 | (27,536) | (21,943) |
| Interest and other expense | (2,609) | (2,318) | (4,199) | (4,153) |
| Interest and other income | 1,723 | 1,834 | 3,266 | 4,053 |
| Loss on early extinguishment of debt | (4,349) | — | (4,349) | — |
| Net (loss) income | $(31,775) | $3,252 | $(32,818) | $(22,043) |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's business segments — loss from operations?
- Lexicon Pharmaceuticals (LXRX) reported business segments — loss from operations of -$26.54M in Q2 2026.
- How has Lexicon Pharmaceuticals's business segments — loss from operations changed year-over-year?
- Lexicon Pharmaceuticals's business segments — loss from operations decreased by 810.4% year-over-year, from $3.74M to -$26.54M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — loss from operations?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — loss from operations has grown at a -21.4% compound annual growth rate (CAGR), from -$100.76M to -$48.91M.
- What does business segments — loss from operations mean?
- The financial result of a segment's operations calculated by subtracting total operating expenses from segment revenues. A negative value indicates that the segment is currently consuming more resources than it generates through commercial activities. This is a primary metric for assessing the segment's path to profitability.
Ask your AI about Lexicon Pharmaceuticals's business segments — loss from operations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude